BLUE
bluebird bio, Inc. (acquired; no BLUE listing)
Is BLUE Halal?
bluebird bio was acquired by Carlyle and SK Capital in June 2025 and BLUE ceased to be publicly listed; the gene-therapy analysis remains qualitative.
What You Should Know
BLUE is a preserved bluebird bio route. The acquisition completed on June 2, 2025, and the common stock ceased trading. bluebird bio's gene therapies for severe diseases remain generally permissible in the qualitative analysis, but no current standalone public-company quantitative screen is applicable.
⚠️ Concerns
- •BLUE ceased public trading after the June 2025 acquisition
- •High treatment cost and access
- •Reimbursement and manufacturing risk
- •BLUE is a preserved private-acquisition alias; the URL is unchanged
Current quantitative Sharia screen
Based on issuer-status figures for the period ended 2025-06-02; calculated 2026-07-15.
- Financial
- Not calculated
- Overall
- Not calculated
Not calculated because bluebird bio became privately held and ceased public listing in June 2025.
- Financial
- Not calculated
- Overall
- Not calculated
No current standalone bluebird bio financial statement is available.
- Financial
- Not calculated
- Overall
- Not calculated
Not calculated for the delisted BLUE security.
- Financial
- Not calculated
- Overall
- Not calculated
BLUE has no current public-market price or market-cap series.
Business-activity disclosure
bluebird bio historically developed gene therapies for severe genetic diseases. Therapeutic gene therapy is generally permissible in principle, but BLUE is no longer a publicly investable security.
Limitation: No current standalone public-company balance sheet, revenue statement or market-cap series is available after the acquisition.
Purification
No current standalone BLUE issuer income is available for purification.
Inputs, assumptions and primary sources
- bluebird bio's sale to Carlyle and SK Capital completed on June 2, 2025; BLUE ceased trading and is no longer publicly listed.
- No parent-company or private-company figures are substituted for a standalone BLUE screen, so numerical ratios are intentionally not calculated.
- The route and existing gene-therapy qualitative analysis are preserved.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →